TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Fetal Growth Factor 21 (FGF21) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma betaine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of Administered Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of Administered Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of Administered Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reference range for plasma iNOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of Front Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of Lateral Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of One Leg Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of Tandem Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants by Family History of Factor VIII Inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Acute Humoral Rejection (AHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Time to successful completion of RT procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving product meeting release criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of administered cell product regarding Graft-versus-Host-Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Number of people identified by high risk or low quality prescribing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in CROPS following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PROPS following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in SUDS following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PRS following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Waist size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical and surgical complication
Endpoint domain: Adverse events/effects
Primary endpoint: Treadmill walk duration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death during hospitalization after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent Trichiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor to Background Ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of All Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of LASIK versus PRK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability of LASIK versus PRK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of LASIK versus PRK
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma acylated Ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma active glugagon-like peptide 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete response to preventive treatment of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elasticity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP-Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal muscle lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical fit of provisional restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Postoperative Delirium (POD)
Endpoint domain: Adverse events/effects
Primary endpoint: Parasite clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of gastrointestinal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Average Daily Pain NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracoronary blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weight change during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in abdominal discomfort and bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Breast Tissue Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximum Tolerance to Transcutaneous Electrical Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in myofibrillar protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in blood glucose range [70-180 mg/dl]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in self-management
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Hamilton Depression Scale-17 (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With a Significant Skin Event
Endpoint domain: Adverse events/effects
Primary endpoint: 3 year progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Serum Vitamin D Level From Baseline to Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TcCO2 Above 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two point change in histological NAFLD activity score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with at least a 30% change in % steatosis relative to screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Visual Acuity (VA) ETDRS >/= 15 Letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Desaturation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in urine flow parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Maximum Nausea Severity
Endpoint domain: Adverse events/effects
Primary endpoint: change in the Measurement of mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of acquired COVID infection
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in maximum voluntary contraction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of postpartum blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in sleep and waking EEG measures
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Measures of performance, attention, alertness, and memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Measures of cardiovascular and metabolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective Reaction Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area of atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to emergence of inadequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre- and post-dialysis levels of BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre- and post-dialysis levels of NTpro-BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of each of the three active ingredients in Biktarvy®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life elimination of each of the three active ingredients in Biktarvy®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the curve of each of the three active ingredients in Biktarvy®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of RT-PCR- or Culture-confirmed Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: T-reg number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of severe and/or frequent hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of active Crohn's Disease (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Medication adherence with BAASIS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication adherence with MARS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Manifest Refraction Spherical Equivalent (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial Natriuretic Peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heparan sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syndecan 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyaluronan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of TensorTip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of stroke and major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Semen to Plasma Ratio of HIV Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of clients obtaining an injectable during their family planning appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of clients obtaining an injectable during their family planning appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Monthly total number of family planning clients by method obtained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Degree of the pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of inhalation agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of angular displacement of lumbar spine and hip joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bat-swing velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of angular displacement of thoracic spine and lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Stroke or Hard TIA
Endpoint domain: Mortality/survival
Primary endpoint: Continuation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Katz Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Treatment emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Suspected and unexpected serious adverse reaction (SUSAR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tooth Color (ΔE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Tissue Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eliminate residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: convert partial remission to complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of headache symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of disease activity parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cancer Survivors interested and willing to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correction of protein energy wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: change in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Reticular Vein Disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage change in Forced Expiratory Volume in 1 s (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain intensity measured by ALPS-Neo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measured by VAS (physician)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measured by VAS (parent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of conversion to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Toxicity of HPR/LXS oral powder
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of the combination of ketoconazole and 4-HPR/LXS oral powder
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Woodcock Johnson Tests of Achievement, Fourth Edition (WJ-IV)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Grade 3 or Greater Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Progression After Allotransplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Six-Minute Walking Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events Are no Greater Than With Treprostinil Infusion Alone
Endpoint domain: Adverse events/effects
Primary endpoint: WHO Functional Class Will Improve or Remain Stable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgeon Evaluation of Improved Monitoring Ability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Surgeon Evaluation of Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean diastolic blood pressure (dBP) at 28, 32 and 36 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cut-off value for DST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With Local and/or General Adverse Events Irrespective of Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Local and/or General SEVERE Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Average 24-hour Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of vital signs abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of standard 12-lead electrocardiogram (ECG) abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Ketosis in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excretion of Ketones in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from disabling epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of Re-Admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biomarkers of neurological injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of CAR-T cells treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stigma perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: occlusion time parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distribution of right-left occlusion force percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/toxicity of the HPV-16 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Acrophobia Questionnaire With Avoidance (AAVQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in retinal anatomy/blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Serum level of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gum inflammation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint health assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to treatment referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resectability (R0) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time in the target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unscheduled visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in Liver Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: size of endometriomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on VAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Vision Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oswestry Disability Index from baseline to 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Oswestry Disability Index from baseline to 52 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning